High levels of circulating insulin-like growth factor-I increase prostate cancer risk: A prospective study in a population-based nonscreened cohort

Journal of Clinical Oncology

Volumn 22, Issue 15, 2004, Pages 3104-3112

  Stattin, Pär ^a   Rinaldi, Sabina ^a   Biessy, Carine ^a   Stenman, Ulf Håkan ^a   Hallmans, Göran ^a   Kaaks, Rudolf ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ARTICLE; CANCER RISK; CONTROLLED STUDY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SWEDEN; BLOOD; COHORT ANALYSIS; MIDDLE AGED; PROSTATE TUMOR; RISK FACTOR; STATISTICAL MODEL;

COHORT STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 4143057115     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.105     Document Type: Article

References (45)

1. Yu H, Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472-1489, 2000
2. LeRoith D, Roberts CT: The insulin-like growth factor system and cancer. Cancer Lett 195:127-137, 2003
3. Dunn SE, Kari FW, French J, et al: Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 57:4667-4672, 1997
4. DiGiovanni J, Kiguchi K, Frijhoff A, et al: Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci U S A 97:3455-3460, 2000
5. Juul A, Bang P, Hertel NT, et al: Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: Relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78:744-752, 1994
6. Le Roith D, Bondy C, Yakar S, et al: The somatomedin hypothesis: 2001. Endocr Rev 22:53-74, 2001
7. Pollard M, Luckert PH, Snyder D: Prevention of prostate cancer and liver tumors in L-W rats by moderate dietary restriction. Cancer 64:686-690, 1989
8. Thissen JP, Ketelslegers JM, Underwood LE: Nutritional regulation of the insulin-like growth factors. Endocr Rev 15:80-101, 1994
9. Kaklamani VG, Linos A, Kaklamani E, et al: Dietary fat and carbohydrates are independently associated with circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 concentrations in healthy adults. J Clin Oncol 17:3291-3298, 1999
10. Probst-Hensch NM, Wang H, Goh VH, et al: Determinants of circulating insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations in a cohort of Singapore men and women. Cancer Epidemiol Biomarkers Prev 12:739-746, 2003
11. Harrela M, Koistinen H, Kaprio J, et al: Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98:2612-2615, 1996
12. Mantzoros CS, Tzonou A, Signorello LB, et al: Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76:1115-1118, 1997
13. Wolk A, Mantzoros CS, Andersson SO, et al: Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 90:911-915, 1998
14. Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 279:563-566, 1998
15. Djavan B, Bursa B, Seitz C. et al: Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology 54:603-606, 1999
16. Harman SM, Metter EJ, Blackman MR, et al: Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 85:4258-4265, 2000
17. Stattin P, Bylund A, Rinaldi S, et al: Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: A prospective study. J Natl Cancer Inst 92:1910-1917, 2000
18. Chokkalingam AP, Pollak M, Fillmore CM, et al: Insulin-like growth factors and prostate cancer: A population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 10:421-427, 2001
19. Khosravi J, Diamandi A, Mistry J, et al: Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J Clin Endocrinol Metab 86:694-699, 2001
20. Oliver SE, Barrass B, Gunnell DJ, et al: Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer. Cancer Epidemiol Biomarkers Prev 13:163-165, 2004
21. Kurek R, Tunn UW, Eckart O, et al: The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer. BJU Int 85:125-129, 2000
22. Baffa R, Reiss K, El-Gabry EA, et al: Low serum insulin-like growth factor 1 (IGF-1): A significant association with prostate cancer. Tech Urol 6:236-239, 2000
23. Finne P, Auvinen A, Koistinen H, et al: Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 85:2744-2747, 2000
24. Chan JM, Stampfer MJ, Ma J, et al: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94:1099-1106, 2002
25. Woodson K, Tangrea JA, Pollak M, et al: Serum insulin-like growth factor I: Tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 63:3991-3994, 2003
26. Li L, Yu H, Schumacher F, et al: Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 14:721-726, 2003
27. Shi R, Berkel HJ, Yu H: Insulin-like growth factor-I and prostate cancer: A meta-analysis. Br J Cancer 85:991-996, 2001
28. Hallmans G, Ågren Å, Johansson G, et al: Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort: Evaluation of risk factors and their interactions. Scand J Public Health 18-24, 2003 (suppl 61)
29. Lindahl B, Weinehall L, Asplund K, et al: Screening for impaired glucose tolerance. Diabetes Care 22:1988-1992, 1999
30. Oncological centre, Umeå University Hospital: Prostate cancer: primary registration in Northern Sweden 1992-2001. http://www. oc.umu.se. 2001
31. International Union Against Cancer: TNM Classification of Malignant Tumors (ed 4). Berlin, Germany, Springer 1992
32. Egevad L: Reproducibility of Gleason grading of prostate cancer can be improved by the use of reference images. Urology 57:291-295, 2001
33. Vessella R, Noteboom J, Lange P: Evaluation of the Abbott IMx Automated Immmunoassay of Prostate-Specific Antigen. Clin Chem 38:2044-2054, 1992
34. SAS Institute: SAS/STAT User's Guide, Version 6.4. Cary, NC, 1989
35. Stenman UH, Leinonen J, Zhang WM, et al: Prostate-specific antigen. Semin Cancer Biol 9:83-93, 1999
36. Partin AW, Mangold LA, Lamm DM, et al: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58:843-848, 2001
37. Zhang Y, Kiel DP, Ellison RC, et al: Bone mass and the risk of prostate cancer: The Framingham Study. Am J Med 113:734-739, 2002
38. Hankinson SE, Willett WC, Colditz GA, et al: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396, 1998
39. Etzioni R, Berry KM, Legler JM, et al: Prostate-specific antigen testing in black and white men: An analysis of medicare claims from 1991-1998. Urology 59:251-255, 2002
40. Cooperberg MR, Lubeck DP, Mehta SS, et al: Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE). J Urol 170:521-527, 2003 (suppl)
41. Bubley GJ, Balk SP, Regan MM, et al: Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy. J Urol 168:2249-2252, 2002
42. Giovannucci E, Rimm EB, Colditz GA, et al: A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85:1571-1579, 1993
43. Giovannucci E, Stampfer MJ, Krithivas K, et al: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 94:3320-3323, 1997
44. Ma J, Pollak MN, Giovannucci E, et al: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620-625, 1999
45. Kaaks R, Rinaldi S, Lukanova A, et al: Correspondence re: Giovannucci et al, A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomark Prev, 9:345-349, 2000. Cancer Epidemiol Biomarkers Prev 10:1103-1104, 2001